ILLUMINA INC, 10-Q filed on 5/5/2017
Quarterly Report
v3.7.0.1
Document and Entity Information - shares
shares in Millions
3 Months Ended
Apr. 02, 2017
Apr. 21, 2017
Document and Entity Information [Abstract]    
Entity Registrant Name Illumina Inc  
Entity Central Index Key 0001110803  
Current Fiscal Year End Date --01-01  
Entity Filer Category Large Accelerated Filer  
Document Type 10-Q  
Document Period End Date Apr. 02, 2017  
Document Fiscal Year Focus 2017  
Document Fiscal Period Focus Q1  
Amendment Flag false  
Entity Common Stock, Shares Outstanding   146
v3.7.0.1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Millions
Apr. 02, 2017
Jan. 01, 2017
Current assets:    
Cash and cash equivalents $ 981 $ 735
Short-term investments 797 824
Accounts receivable, net 368 381
Inventory 299 300
Prepaid expenses and other current assets 72 78
Total current assets 2,517 2,318
Property and equipment, net 734 713
Goodwill 771 776
Intangible assets, net 207 243
Deferred tax assets 83 123
Other assets 286 108
Total assets 4,598 4,281
Current liabilities:    
Accounts payable 142 138
Accrued liabilities 386 343
Build-to-suit lease liability 192 223
Long-term debt, current portion 1 1
Total current liabilities 721 705
Long-term debt 1,055 1,048
Other long-term liabilities 212 214
Redeemable noncontrolling interests 59 44
Stockholders’ equity:    
Common stock 2 2
Additional paid-in capital 2,798 2,733
Accumulated other comprehensive loss (1) (1)
Retained earnings 1,897 1,485
Treasury stock, at cost (2,145) (2,022)
Total Illumina stockholders' equity 2,551 2,197
Noncontrolling interests   73
Total stockholders’ equity 2,551 2,270
Total liabilities and stockholders’ equity $ 4,598 $ 4,281
v3.7.0.1
Condensed Consolidated Statements of Income (Unaudited) - USD ($)
shares in Millions, $ in Millions
3 Months Ended
Apr. 02, 2017
Apr. 03, 2016
Revenue:    
Product revenue $ 491 $ 483
Service and other revenue 107 89
Total revenue 598 572
Cost of revenue:    
Cost of product revenue 166 125
Cost of service and other revenue 53 39
Amortization of acquired intangible assets 11 11
Total cost of revenue 230 175
Gross profit 368 397
Operating expense:    
Research and development 145 124
Selling, general and administrative 163 150
Legal contingencies 8 2
Total operating expense 316 276
Income from operations 52 121
Other income (expense):    
Interest income 4 1
Interest expense (8) (8)
Other income, net 455 2
Total other income (expense), net 451 (5)
Income before income taxes 503 116
Provision for income taxes 155 28
Consolidated net income 348 88
Add: Net loss attributable to noncontrolling interests 19 2
Net income attributable to Illumina stockholders 367 90
Net income attributable to Illumina stockholders for earnings per share $ 366 $ 90
Earnings per share attributable to Illumina stockholders:    
Basic (in dollars per share) $ 2.50 $ 0.61
Diluted (in dollars per share) $ 2.48 $ 0.60
Shares used in computing earnings per common share:    
Basic (in shares) 146 147
Diluted (in shares) 147 148
v3.7.0.1
Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($)
$ in Millions
3 Months Ended
Apr. 02, 2017
Apr. 03, 2016
Statement of Comprehensive Income [Abstract]    
Consolidated net income $ 348 $ 88
Unrealized gain on available-for-sale securities, net of deferred tax   2
Total consolidated comprehensive income 348 90
Add: Comprehensive loss attributable to noncontrolling interests 19 2
Comprehensive income attributable to Illumina stockholders $ 367 $ 92
v3.7.0.1
Condensed Consolidated Statement of Stockholders' Equity Statement - 3 months ended Apr. 02, 2017 - USD ($)
$ in Millions
Total
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Other Comprehensive Income [Member]
Retained Earnings [Member]
Treasury Stock [Member]
Noncontrolling Interests [Member]
Beginning balance at Jan. 01, 2017 $ 2,270 $ 2 $ 2,733 $ (1) $ 1,485 $ (2,022) $ 73
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income (loss) 360       367   (7)
Issuance of common stock, net of repurchases (100)   23     (123)  
Share-based compensation 50   50        
Adjustment to the carrying value of redeemable noncontrolling interests (12)   (12)        
Vesting of redeemable equity awards (10)   (10)        
Cumulative-effect adjustment from adoption of ASU 2016-09 48   3   45    
Deconsolidation of GRAIL (55)   11       (66)
Ending balance at Apr. 02, 2017 $ 2,551 $ 2 $ 2,798 $ (1) $ 1,897 $ (2,145) $ 0
v3.7.0.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Millions
3 Months Ended
Apr. 02, 2017
Apr. 03, 2016
Cash flows from operating activities:    
Consolidated net income $ 348 $ 88
Adjustments to reconcile net income to net cash provided by operating activities:    
Gain on deconsolidation of GRAIL (453)  
Depreciation expense 26 21
Amortization of intangible assets 12 12
Share-based compensation expense 50 35
Accretion of debt discount 7 8
Deferred income taxes 86 (6)
Impairment of intangible assets 23  
Other (2) (1)
Changes in operating assets and liabilities:    
Accounts receivable 16 (13)
Inventory 1 (17)
Prepaid expenses and other current assets 2 (3)
Other assets (1) (2)
Accounts payable (3) 3
Accrued liabilities 52 (30)
Other long-term liabilities 4 4
Net cash provided by operating activities 168 99
Cash flows from investing activities:    
Purchases of available-for-sale securities (61) (85)
Sales of available-for-sale securities 40 39
Maturities of available-for-sale securities 48 76
Net cash paid for acquisitions   (18)
Proceeds from sale of GRAIL securities 278  
Deconsolidation of GRAIL cash (52)  
Net purchases of strategic investments 7 3
Purchases of property and equipment (83) (53)
Net cash provided by (used in) investing activities 163 (44)
Cash flows from financing activities:    
Payments on financing obligations (1) (76)
Payments on acquisition related contingent consideration liability   (29)
Common stock repurchases (101)  
Taxes paid related to net share settlement of equity awards (22) (69)
Proceeds from issuance of common stock 22 23
Contributions from noncontrolling interest owners 16 80
Net cash used in financing activities (86) (71)
Effect of exchange rate changes on cash and cash equivalents 1 2
Net increase (decrease) in cash and cash equivalents 246 (14)
Cash and cash equivalents at beginning of period 735 769
Cash and cash equivalents at end of period $ 981 $ 755
v3.7.0.1
Basis of Presentation and Summary of Significant Accounting Policies
3 Months Ended
Apr. 02, 2017
Accounting Policies [Abstract]  
Basis of Presentation and Summary of Significant Accounting Policies
Basis of Presentation and Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. Interim financial results are not necessarily indicative of results anticipated for the full year. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and footnotes included in the Company’s Annual Report on Form 10-K for the fiscal year ended January 1, 2017, from which the balance sheet information herein was derived. The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expense, and related disclosure of contingent assets and liabilities. Actual results could differ from those estimates.

The unaudited condensed consolidated financial statements include the accounts of the Company, its wholly-owned subsidiaries, majority-owned or controlled companies, and variable interest entities (VIEs) for which the Company is the primary beneficiary. All intercompany transactions and balances have been eliminated in consolidation. Effective February 28, 2017, Illumina deconsolidated GRAIL, Inc.’s financial statements. In management’s opinion, the accompanying financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results for the interim periods presented.

The Company evaluates its ownership, contractual and other interests in entities that are not wholly-owned by the Company to determine if these entities are VIEs, and, if so, whether the Company is the primary beneficiary of the VIE. In determining whether the Company is the primary beneficiary of a VIE and is therefore required to consolidate the VIE, the Company applies a qualitative approach that determines whether it has both (1) the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and (2) the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE. The Company continuously assesses whether it is the primary beneficiary of a VIE as changes to existing relationships or future transactions may result in the consolidation or deconsolidation, as the case may be. The Company has not provided financial or other support during the periods presented to its VIEs that it was not previously contractually required to provide.

The equity method is used to account for investments in which the Company has the ability to exercise significant influence, but not control, over the investee. Such investments are recorded within other assets, and the share of net income or losses of equity investments is recognized on a one quarter lag in other income, net.

Redeemable Noncontrolling Interests

Noncontrolling interests represent the portion of equity (net assets) in a consolidated entity that is not wholly-owned by the Company that is not attributable, directly or indirectly, to the Company. Noncontrolling interests with embedded contingent redemption features, such as put rights, that are not solely within the Company’s control are considered redeemable noncontrolling interests. Redeemable noncontrolling interests are presented outside of stockholders’ equity on the condensed consolidated balance sheets.

Segment Information
 
The Company is organized into three operating segments for purposes of evaluating its business operations and reviewing its financial results. One segment consists of Illumina’s core operations (Core Illumina). The other two segments relate to the activities of the Company’s consolidated variable interest entities (Consolidated VIEs), GRAIL and Helix, and are reported on an aggregate basis. Following the GRAIL deconsolidation on February 28, 2017, the Consolidated VIEs no longer include GRAIL. For further information on the Company’s segments, refer to note “9. Segment Information”.

Fiscal Year

The Company’s fiscal year consists of 52 or 53 weeks ending the Sunday closest to December 31, with quarters of 13 or 14 weeks ending the Sunday closest to March 31, June 30, September 30, and December 31. The three months ended April 2, 2017 and April 3, 2016 were both 13 weeks.

Reclassifications

Certain prior period amounts have been reclassified to conform to the current period presentation.

Significant Accounting Policies

During the three months ended April 2, 2017, there have been no changes to the Company’s significant accounting policies as described in the Annual Report on Form 10-K for the fiscal year ended January 1, 2017.

Recently Adopted Accounting Pronouncements

In March 2016, the Financial Accounting Standards Board issued Accounting Standard Update (ASU) 2016-09, Compensation - Stock Compensation (Topic 718), which aims to simplify the accounting for share-based payment transactions, including accounting for income taxes, classification on the statement of cash flows, accounting for forfeitures, and classification of awards as either liabilities or equity. This ASU is effective for the Company beginning in the first quarter of 2017.

Under the ASU, excess tax benefits from share-based payment arrangements are classified as discrete items within the provision for income taxes, rather than recognizing excess tax benefits in additional paid-in capital. As of April 2, 2017, the Company recorded $45 million, net, to retained earnings primarily related to unrealized tax benefits associated with share-based compensation. During the three months ended April 2, 2017, excess tax benefits of $8 million were reflected as a component of the provision for income taxes.

In addition, under the ASU, excess income tax benefits from share-based compensation arrangements are classified as cash flow from operations, rather than cash flow from financing activities. The Company has elected to apply the cash flow classification guidance retrospectively and reclassified $59 million from financing activity to operating activity for the three months ended April 3, 2016.

Recently Issued Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers (Topic 606). The new standard is based on the principle that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Since its initial release, the FASB has issued several amendments to the standard, which include clarification of accounting guidance related to identification of performance obligations, intellectual property licenses, and principal vs. agent considerations.

ASU 2014-09 and all subsequent amendments (collectively, the “new standards”) will be effective for the Company beginning in the first quarter of 2018 and may be applied using either the full retrospective method, in which case the standard would be applied to each prior reporting period presented, or the modified retrospective method, in which case the cumulative effect of applying the standard would be recognized at the date of initial application.

The Company formed an implementation team in 2016 to oversee adoption of the new standards. The implementation team has completed its initial assessment of the new standards, including a detailed review of the Company’s contract portfolio and revenue streams, particularly around product revenues, to identify potential differences in accounting as a result of the new standards. It performed an analysis of those differences and formed preliminary conclusions on the expected changes. While the team’s analysis to date suggests the impact of adoption will not have a material impact on the Company’s existing revenue accounting policies or financial statements, there are a number of steps in the team’s project plan that remain to be completed including: finalizing contract reviews, evaluating the impact on the Company’s services and other revenue streams, and working through anticipated changes to systems, business processes and controls to support the adoption of the new standards. Assuming the impact is not material, the Company expects to adopt the new standards using the modified retrospective method with an adjustment to beginning retained earnings for the cumulative effect of the change.

In January 2016, the Financial Accounting Standards Board issued ASU 2016-01, Financial Instruments - Overall (Subtopic 825-10), which requires equity investments (other than those accounted for under the equity method or those that result in consolidation) to be measured at fair value, with changes in fair value recognized in net income. ASU 2016-01 will be effective for the Company beginning in the first quarter of 2018. The Company anticipates that the adoption of ASU 2016-01 may increase the volatility of other income and expense, net, as a result of the remeasurement of the Company’s cost-method investments.

In February 2016, the Financial Accounting Standards Board issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. ASU 2016-02 will be effective for the Company beginning in the first quarter of 2019. ASU 2016-02 will be adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company is currently evaluating the impact of ASU 2016-02 on its consolidated financial statements.

In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available for sale debt securities. The ASU is effective for the Company beginning in the first quarter of 2020, with early adoption permitted.  The Company is currently evaluating the impact of ASU 2016-13 on its consolidated financial statements.

Earnings per Share

Basic earnings per share attributable to Illumina stockholders is computed based on the weighted average number of common shares outstanding during the period. Diluted earnings per share attributable to Illumina stockholders is computed based on the sum of the weighted average number of common shares and potentially dilutive common shares outstanding during the period. Per-share earnings of our VIEs are included in the Company’s consolidated basic and diluted earnings per share computations based on the Company’s share of the VIEs’ securities.

Potentially dilutive common shares consist of shares issuable under convertible senior notes, equity awards, and warrants. Convertible senior notes have a dilutive impact when the average market price of the Company’s common stock exceeds the applicable conversion price of the respective notes. Potentially dilutive common shares from equity awards and warrants are determined using the average share price for each period under the treasury stock method. In addition, proceeds from exercise of equity awards and warrants, and the average amount of unrecognized compensation expense for equity awards are assumed to be used to repurchase shares. In loss periods, basic net loss per share and diluted net loss per share are identical because the otherwise dilutive potential common shares become anti-dilutive and are therefore excluded.

The following table presents the calculation of weighted average shares used to calculate basic and diluted earnings per share (in millions):
 
Three Months Ended
 
April 2,
2017
 
April 3,
2016
Weighted average shares outstanding
146

 
147

Effect of potentially dilutive common shares from:
 
 
 
Equity awards
1

 
1

Weighted average shares used in calculating diluted earnings per share
147

 
148

Potentially dilutive shares excluded from calculation due to anti-dilutive effect
1

 
1

v3.7.0.1
Balance Sheet Account Details
3 Months Ended
Apr. 02, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Balance Sheet Account Details
Balance Sheet Account Details

Short-Term Investments

The following is a summary of short-term investments (in millions):
 
April 2, 2017
 
January 1, 2017
 
Amortized
Cost
 
Gross
Unrealized
Losses
 
Estimated
Fair Value
 
Amortized
Cost
 
Gross
Unrealized
Losses
 
Estimated
Fair Value
Available-for-sale securities:
 
 
 
 
 
 
 
 
 
 
 
Debt securities in government sponsored entities
$
31

 
$

 
$
31

 
$
34

 
$

 
$
34

Corporate debt securities
464

 
(1
)
 
463

 
478

 
(2
)
 
476

U.S. Treasury securities
304

 
(1
)
 
303

 
316

 
(2
)
 
314

Total available-for-sale securities
$
799

 
$
(2
)
 
$
797

 
$
828

 
$
(4
)
 
$
824



Realized gains and losses are determined based on the specific identification method and are reported in interest income.

Contractual maturities of available-for-sale debt securities as of April 2, 2017 were as follows (in millions):
 
Estimated
Fair Value
Due within one year
$
383

After one but within five years
414

Total
$
797


The Company has the ability, if necessary, to liquidate any of its cash equivalents and short-term investments in order to meet its liquidity needs in the next 12 months. Accordingly, those investments with contractual maturities greater than one year from the date of purchase nonetheless are classified as short-term on the accompanying condensed consolidated balance sheets.

Strategic Investments

As of April 2, 2017 and January 1, 2017, the aggregate carrying amounts of the Company’s cost-method investments in non-publicly traded companies included in other assets were $235 million and $57 million, respectively, included in other assets. Revenue recognized from transactions with such companies was $23 million and $13 million, respectively, for the three months ended April 2, 2017 and April 3, 2016.

The Company’s cost-method investments are assessed for impairment quarterly. The Company determines that it is not practicable to estimate the fair value of its cost-method investments on a regular basis and does not reassess the fair value of cost-method investments unless there are identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investments. No material impairment losses were recorded during the three months ended April 2, 2017 or April 3, 2016.

The Company invests in a venture capital investment fund (the Fund) with a capital commitment of $100 million that is callable over ten years. The Company’s investment in the Fund is accounted for as an equity method investment. The carrying amounts included in other assets were $11 million and $10 million as of April 2, 2017 and January 1, 2017, respectively.

Inventory

Inventory consists of the following (in millions):
 
April 2,
2017
 
January 1,
2017
Raw materials
$
101

 
$
102

Work in process
162

 
161

Finished goods
36

 
37

Total inventory
$
299

 
$
300



Property and Equipment

Property and equipment, net consists of the following (in millions):
 
April 2,
2017
 
January 1,
2017
Leasehold improvements
$
273

 
$
270

Machinery and equipment
278

 
274

Computer hardware and software
168

 
156

Furniture and fixtures
26

 
24

Building
9

 
9

Construction in progress
326

 
307

Total property and equipment, gross
1,080

 
1,040

Accumulated depreciation
(346
)
 
(327
)
Total property and equipment, net
$
734

 
$
713


Property and equipment, net included accrued expenditures of $60 million and $26 million for the three months ended April 2, 2017 and April 3, 2016, respectively, which were excluded from the condensed consolidated statements of cash flows. For the three months ended April 2, 2017 and April 3, 2016, accrued expenditures includes $27 million and $10 million, respectively, in construction in progress recorded under build-to-suit lease accounting.

Intangible Assets and Goodwill

Changes to the Company’s goodwill balance during the three months ended April 2, 2017 are as follows (in millions):
 
Goodwill
Balance as of January 1, 2017
$
776

GRAIL deconsolidation
(5
)
Balance as of April 2, 2017
$
771


The Company regularly performs reviews to determine if any event has occurred that may indicate its identifiable intangible assets are potentially impaired.  During the three months ended April 2, 2017, the Company performed a recoverability test when the planned use of a finite-lived acquired intangible asset changed, resulting in an impairment charge of $18 million recorded in cost of product revenue. Additionally, the Company recorded a $5 million impairment charge of in-process research and development as it was determined the project had no future alternative use.

Derivatives

The Company is exposed to foreign exchange rate risks in the normal course of business. The Company enters into foreign exchange contracts to manage foreign currency risks related to monetary assets and liabilities that are denominated in currencies other than the U.S. dollar. These foreign exchange contracts are carried at fair value in other assets or other liabilities and are not designated as hedging instruments. Changes in the value of the derivative are recognized in other income, net, along with the remeasurement gain or loss on the foreign currency denominated assets or liabilities.

As of April 2, 2017, the Company had foreign exchange forward contracts in place to hedge exposures in the euro, Japanese yen, Australian dollar, and Canadian dollar. As of April 2, 2017 and January 1, 2017, the total notional amounts of outstanding forward contracts in place for foreign currency purchases were $92 million and $69 million, respectively.

Accrued Liabilities

Accrued liabilities consist of the following (in millions):
 
April 2,
2017
 
January 1,
2017
Deferred revenue, current portion
$
122

 
$
121

Accrued compensation expenses
99

 
112

Accrued taxes payable
77

 
32

Customer deposits
31

 
20

Other
57

 
58

Total accrued liabilities
$
386

 
$
343


Warranties

The Company generally provides a one-year warranty on instruments. Additionally, the Company provides a warranty on consumables through the expiration date, which generally ranges from six to twelve months after the manufacture date. At the time revenue is recognized, the Company establishes an accrual for estimated warranty expenses based on historical experience as well as anticipated product performance. The Company periodically reviews its warranty reserve for adequacy and adjusts the warranty accrual, if necessary, based on actual experience and estimated costs to be incurred. Warranty expense is recorded as a component of cost of product revenue.

Changes in the Company’s reserve for product warranties during the three months ended April 2, 2017 and April 3, 2016 are as follows (in millions):
 
Three Months Ended
 
April 2,
2017
 
April 3,
2016
Balance at beginning of period
$
13

 
$
17

Additions charged to cost of product revenue
4

 
7

Repairs and replacements
(5
)
 
(8
)
Balance at end of period
$
12

 
$
16


Leases

Changes in the Company’s facility exit obligation related to its former headquarters lease during the three months ended April 2, 2017 and April 3, 2016 are as follows (in millions):
 
Three Months Ended
 
April 2,
2017
 
April 3,
2016
Balance at beginning of period
$
19

 
$
22

Cash payments
(1
)
 
(1
)
Balance at end of period
$
18

 
$
21

On February 22, 2017, the Company entered into a lease agreement for a building under construction in Madison, Wisconsin. Minimum lease payments during the initial 15-year term are estimated to be $46 million.

The Company evaluates whether it is the accounting owner of leased assets during the construction period when the Company is involved in the construction of leased assets. Including the Madison lease noted above, the Company is considered the owner of three construction projects for accounting purposes only under build-to-suit lease accounting due to certain indemnification obligations related to the construction. As of April 2, 2017 and January 1, 2017, the Company has recorded $192 million and $223 million, respectively, in project construction costs paid or reimbursed by the landlord as construction in progress and a corresponding build-to-suit lease liability. During the three months ended April 2, 2017, the Company deconsolidated GRAIL, as further described below, and removed $58 million of construction in progress and the corresponding build-to-suit lease liability.
 
Investments in Consolidated Variable Interest Entities

GRAIL, Inc.

In January 2016, the Company obtained a majority equity ownership interest in GRAIL, a company formed with unrelated third party investors to develop a blood test for early-stage cancer detection. The Company determined that GRAIL was a variable interest entity as the entity lacked sufficient equity to finance its activities without additional support. Additionally, the Company determined that it had (a) control of GRAIL’s board of directors, which had unilateral power over the activities that most significantly impacted the economic performance of GRAIL and (b) the obligation to absorb losses of and the right to receive benefits from GRAIL that were potentially significant to GRAIL. As a result, the Company was deemed to be the primary beneficiary of GRAIL and was required to consolidate GRAIL.

In January 2016, GRAIL completed its Series A convertible preferred stock financing, raising $120 million, of which the Company invested $40 million. Additionally, the Company and GRAIL executed a long-term supply agreement in which the Company contributed certain perpetual licenses, employees, and discounted supply terms in exchange for 113 million shares of GRAIL’s Class B common stock. Such contributions were recorded at their historical basis as they remained within the control of the Company. The $80 million received by GRAIL from unrelated third party investors upon issuance of its Series A convertible preferred stock was classified as noncontrolling interests in stockholders’ equity on the Company’s condensed consolidated balance sheet.

In June 2016, GRAIL authorized for issuance 98 million shares of Series A-1 convertible preferred stock, all of which were issued to Illumina in exchange for 98 million shares of Illumina’s Class B common stock. As a result of the exchange, Illumina recorded a $10 million deemed dividend net of tax of $10 million through equity, which was eliminated in consolidation.

Deconsolidation of GRAIL, Inc.

On February 28, 2017, GRAIL completed the initial close of its Series B preferred stock financing, raising over $900 million, in which the Company did not participate. Concurrent with the financing, GRAIL repurchased 35 million shares of its Series A preferred stock and approximately 34 million shares of its Series A-1 preferred stock held by the Company for an aggregate purchase price of $278 million. At this time, the Company ceased to have a controlling financial interest in GRAIL and the Company’s equity ownership was reduced from 52% to 19%. Additionally, the Company’s voting interest was reduced to 13%, and the Company no longer has representation on GRAIL’s board of directors. As a result, the Company deconsolidated GRAIL’s financial statements effective February 28, 2017. In connection with the financing, the Company entered into an agreement with GRAIL that (i) requires the Company to purchase Series B preferred shares sufficient to retain a 19% ownership interest as of April 30, 2017, and (ii) provides the Company the right to purchase additional GRAIL Series B preferred shares, should the Company’s ownership interest in GRAIL fall below 19% after April 30, 2017. As of April 30, 2017, the Company’s purchase obligation is $14 million.

The operations of GRAIL from January 2, 2017 up to the date of deconsolidation are included in the accompanying condensed consolidated statements of income for the three months ended April 2, 2017. During this period, the Company absorbed approximately 50% of GRAIL’s losses based upon its proportional ownership of GRAIL’s common stock.

For the three months ended April 2, 2017, the Company recorded a pretax gain of $453 million included in other income and expense, net, of which $159 million relates to the remeasurement of the Company’s retained equity interest to its fair value. The pretax gain on deconsolidation includes (i) the consideration received from GRAIL for its repurchase of a portion of the Company’s ownership interest, (ii) the derecognition of the carrying amounts of GRAIL’s assets and liabilities, (iii) the derecognition of the noncontrolling interest related to GRAIL and (iv) the recording of the Company’s remaining interest in GRAIL at fair value. This fair value measurement of the Company’s remaining interest was derived using the market approach. Significant estimates and assumptions required for this valuation included, but were not limited to, various Black-Scholes option-pricing model assumptions as of the date of deconsolidation and estimated discounts for lack of marketability related to the equity securities. These unobservable inputs, which represent a Level 3 measurement, are supported by little or no market activity and reflect the Company’s own assumptions in measuring fair value. 

The Company’s retained investment in GRAIL is accounted for under the cost method. As of April 2, 2017, the Company has recorded $171 million in other assets related to this investment. As of April 2, 2017, the Company holds 5 million Series A preferred shares and approximately 78 million Class A common shares of GRAIL, or approximately 19% of GRAIL’s outstanding stock.

In connection with the deconsolidation of GRAIL, the parties amended their long-term supply agreement (the Supply Agreement), including the discounted supply terms. The repurchase and supply arrangements, which were entered into concurrently, contain various elements and, as such, are deemed to be an arrangement with multiple deliverables as defined under the respective authoritative accounting guidance. The Company determined that each of the elements, which include the purchase obligation, the purchase right and services to be provided in accordance with the long-term supply agreement, were at, or approximated, fair value on a standalone basis, and therefore, there was no discount to allocate among the deliverables. As such, none of the deconsolidation gain was allocated to these elements.

Helix Holdings I, LLC

In July 2015, the Company obtained a 50% voting equity ownership interest in Helix Holdings I, LLC (Helix), a limited liability company formed with unrelated third party investors to pursue the development and commercialization of a marketplace for consumer genomics. The Company determined that Helix is a variable interest entity as the holders of the at-risk equity investments as a group lack the power to direct the activities of Helix that most significantly impact Helix’s economic performance. Additionally, the Company determined that it has (a) unilateral power over one of the activities that most significantly impacts the economic performance of Helix through its contractual arrangements and no one individual party has unilateral power over the remaining significant activities of Helix and (b) the obligation to absorb losses of and the right to receive benefits from Helix that are potentially significant to Helix. As a result, the Company is deemed to be the primary beneficiary of Helix and is required to consolidate Helix.

As contractually committed, the Company contributed certain perpetual licenses, instruments, intangibles, initial laboratory setup, and discounted supply terms in exchange for voting equity interests in Helix. Such contributions are recorded at their historical basis as they remain within the control of the Company. Helix is financed through cash contributions made by the third party investors in exchange for voting equity interests in Helix.

Certain noncontrolling Helix investors may require the Company to redeem all noncontrolling interests in cash at the then approximate fair market value. The fair value of the redeemable noncontrolling interests is considered a Level 3 instrument. Such redemption right is exercisable at the option of certain noncontrolling interest holders after January 1, 2021, provided that a bona fide pursuit of the sale of Helix has occurred and an initial public offering of Helix has not been completed.

As the contingent redemption is outside of the control of Illumina, the redeemable noncontrolling interests in Helix are classified outside of stockholders’ equity on the accompanying condensed consolidated balance sheets. The balance of the redeemable noncontrolling interests is reported at the greater of its carrying value after receiving its allocation of Helix’s profits and losses or its estimated redemption value at each reporting date. As of April 2, 2017, the noncontrolling shareholders and Illumina each held 50% of Helix’s outstanding voting equity interests.

The assets and liabilities of Helix are not significant to the Company’s financial position as of April 2, 2017. Helix has an immaterial impact on the Company’s condensed consolidated statements of income and cash flows for the three months ended April 2, 2017.

As of April 2, 2017, the accompanying condensed consolidated balance sheet includes $5 million of cash and cash equivalents attributable to Helix that will be used to settle their respective obligations and will not be available to settle obligations of the Company.

Redeemable Noncontrolling Interests

The activity of the redeemable noncontrolling interests during the three months ended April 2, 2017 is as follows (in millions):
 
Redeemable Noncontrolling Interests
Balance as of January 1, 2017
$
44

Amount released from escrow
16

Vesting of redeemable equity awards
10

Net loss attributable to noncontrolling interests
(12
)
Adjustment up to the redemption value
12

Deconsolidation of GRAIL
(11
)
Balance as of April 2, 2017
$
59

v3.7.0.1
Fair Value Measurements
3 Months Ended
Apr. 02, 2017
Fair Value Disclosures [Abstract]  
Fair Value Measurements
Fair Value Measurements

The following table presents the Company’s hierarchy for assets and liabilities measured at fair value on a recurring basis as of April 2, 2017 and January 1, 2017 (in millions):
 
April 2, 2017
 
January 1, 2017
 
Level 1
 
Level 2
 
Level 3
 
Total
 
Level 1
 
Level 2
 
Level 3
 
Total
Assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Money market funds (cash equivalents)
$
689

 
$

 
$

 
$
689

 
$
386

 
$

 
$

 
$
386

Debt securities in government-sponsored entities

 
31

 

 
31

 

 
34

 

 
34

Corporate debt securities

 
463

 

 
463

 

 
476

 

 
476

U.S. Treasury securities
303

 

 

 
303

 
314

 

 

 
314

Deferred compensation plan assets

 
32

 

 
32

 

 
31

 

 
31

Total assets measured at fair value
$
992

 
$
526

 
$

 
$
1,518

 
$
700

 
$
541

 
$

 
$
1,241

Liabilities:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acquisition related contingent consideration liabilities
$

 
$

 
$
3

 
$
3

 
$

 
$

 
$
4

 
$
4

Deferred compensation liability

 
30

 

 
30

 

 
29

 

 
29

Total liabilities measured at fair value
$

 
$
30

 
$
3

 
$
33

 
$

 
$
29

 
$
4

 
$
33



The Company holds available-for-sale securities that consist of highly liquid, investment grade debt securities. The Company considers information provided by the Company’s investment accounting and reporting service provider in the measurement of fair value of its debt securities. The investment service provider provides valuation information from an industry-recognized valuation service. Such valuations may be based on trade prices in active markets for identical assets or liabilities (Level 1 inputs) or valuation models using inputs that are observable either directly or indirectly (Level 2 inputs), such as quoted prices for similar assets or liabilities, yield curve, volatility factors, credit spreads, default rates, loss severity, current market and contractual prices for the underlying instruments or debt, broker and dealer quotes, as well as other relevant economic measures. The Company’s deferred compensation plan assets consist primarily of investments in life insurance contracts carried at cash surrender value, which reflects the net asset value of the underlying publicly traded mutual funds. The Company performs control procedures to corroborate the fair value of its holdings, including comparing valuations obtained from its investment service provider to valuations reported by the Company’s asset custodians, validation of pricing sources and models, and review of key model inputs if necessary.
v3.7.0.1
Debt
3 Months Ended
Apr. 02, 2017
Debt Disclosure [Abstract]  
Debt
Debt

Convertible Senior Notes

As of April 2, 2017, the Company had outstanding $633 million in principal amount of 0% convertible senior notes due June 15, 2019 (2019 Notes) and $517 million in principal amount of 0.5% convertible senior notes due June 15, 2021 (2021 Notes).

0% Convertible Senior Notes due 2019 and 0.5% Convertible Senior Notes due 2021

In June 2014, the Company issued $633 million aggregate principal amount of 2019 Notes and $517 million aggregate principal amount of 2021 Notes. The Company used the net proceeds plus cash on hand to repurchase a portion of the outstanding 2016 Notes in privately negotiated transactions concurrently with the issuance of the 2019 and 2021 Notes. The 2019 and 2021 Notes’ mature on June 15, 2019 and June 15, 2021, respectively, and the implied estimated effective rates of the liability components of the Notes were 2.9% and 3.5%, respectively, assuming no conversion.

Both the 2019 and 2021 Notes will be convertible into cash, shares of common stock, or a combination of cash and shares of common stock, at the Company's election, based on an initial conversion rate, subject to adjustment, of 3.9318 shares per $1,000 principal amount of the notes (which represents an initial conversion price of approximately $254.34 per share), only in the following circumstances and to the following extent: (1) during the five business-day period after any 10 consecutive trading day period (the measurement period) in which the trading price per 2019 and 2021 Note for each day of such measurement period was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate on each such day; (2) during any calendar quarter (and only during that quarter) after the calendar quarter ending September 30, 2014, if the last reported sale price of the Company’s common stock for 20 or more trading days in the period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter exceeds 130% of the applicable conversion price in effect on the last trading day of the immediately preceding calendar quarter; (3) upon the occurrence of specified events described in the indenture for the 2019 and 2021 Notes; and (4) at any time on or after March 15, 2019 for the 2019 Notes, or March 15, 2021 for the 2021 Notes, through the second scheduled trading day immediately preceding the maturity date.

Neither the 2019 nor the 2021 Notes were convertible as of April 2, 2017, and had no dilutive impact during the three months ended April 2, 2017. If the 2019 and 2021 Notes were converted as of April 2, 2017, the if-converted value would not exceed the principal amount.

0.25% Convertible Senior Notes due 2016

In 2011, the Company issued $920 million aggregate principal amount of 0.25% convertible senior notes due 2016 (2016 Notes) with a maturity date of March 15, 2016. The effective rate of the liability component was estimated to be 4.5%. Based upon meeting the stock trading price conversion requirement during the three months ended March 30, 2014, the 2016 Notes became convertible on April 1, 2014 through, and including, March 11, 2016. All notes were converted by March 11, 2016.

Summary of Convertible Senior Notes

The following table summarizes information about the equity and liability components of all convertible senior notes outstanding as of the period reported (dollars in millions). The fair values of the respective notes outstanding were measured based on quoted market prices, and is a Level 2 measurement.
 
April 2,
2017
 
January 1,
2017
Principal amount of convertible notes outstanding
$
1,150

 
$
1,150

Unamortized discount of liability component
(98
)
 
(105
)
Net carrying amount of liability component in long-term debt
$
1,052

 
$
1,045

Carrying value of equity component, net of debt issuance cost
$
161

 
$
161

Fair value of outstanding notes
$
1,178

 
$
1,108

Weighted-average remaining amortization period of discount on the liability component
3.4 years

 
3.6 years



Other

As of April 2, 2017 and January 1, 2017, the accompanying condensed consolidated balance sheets include $1 million and $3 million in current and long-term debt, respectively, related to an outstanding line of credit held by Helix in each of the respective periods.
v3.7.0.1
Share-based Compensation Expense
3 Months Ended
Apr. 02, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Share-based Compensation Expense
Share-based Compensation Expense

Share-based compensation expense for all stock awards consists of the following (in millions):
 
Three Months Ended
 
April 2,
2017
 
April 3,
2016
Cost of product revenue
$
3

 
$
2

Research and development
14

 
11

Selling, general and administrative
33

 
22

Share-based compensation expense before taxes
50

 
35

Related income tax benefits
(11
)
 
(8
)
Share-based compensation expense, net of taxes
$
39

 
$
27



The assumptions used for the specified reporting periods and the resulting estimates of weighted-average fair value per share for stock purchased under the Employee Stock Purchase Plan (ESPP) during the three months ended April 2, 2017 are as follows:
 
Employee Stock Purchase Rights
Risk-free interest rate
0.65% - 0.83%

Expected volatility
44
%
Expected term
0.5 - 1.0 year

Expected dividends
0
%
Weighted-average fair value per share
$
46.67



As of April 2, 2017, approximately $316 million of unrecognized compensation cost related to stock options, restricted stock, and ESPP shares granted to date is expected to be recognized over a weighted-average period of approximately 2.6 years.
v3.7.0.1
Stockholders' Equity
3 Months Ended
Apr. 02, 2017
Equity [Abstract]  
Stockholders' Equity
Stockholders’ Equity

As of April 2, 2017, approximately 6.2 million shares remained available for future grants under the 2015 Stock Plan and the 2005 Solexa Equity Plan.

Restricted Stock

The Company’s restricted stock activity and related information for the three months ended April 2, 2017 is as follows (units in thousands):
 
Restricted
Stock Awards
(RSA)
 
Restricted
Stock Units
(RSU)
 
Performance
Stock Units
(PSU)(1)
 
Weighted-Average
Grant-Date Fair Value per Share
 
 
 
 
RSA
 
RSU
 
PSU
Outstanding at January 1, 2017
32

 
2,293

 
460

 
$
136.30

 
$
141.80

 
$
158.66

Awarded

 
45

 
23

 
$

 
$
153.64

 
$
139.83

Vested

 
(127
)
 

 
$

 
$
95.06

 
$

Cancelled

 
(66
)
 
(33
)
 
$

 
$
146.83

 
$
185.43

Outstanding at April 2, 2017
32

 
2,145

 
450

 
$
136.30

 
$
144.69

 
$
155.72


______________________________________
(1)
The number of units reflect the estimated number of shares to be issued at the end of the performance period.

Stock Options

The Company’s stock option activity under all stock option plans during the three months ended April 2, 2017 is as follows:
 
Options
(in thousands)
 
Weighted-Average
Exercise Price
Outstanding at January 1, 2017
1,045

 
$
48.56

Exercised
(107
)
 
$
43.65

Outstanding at April 2, 2017
938

 
$
49.13



At April 2, 2017, outstanding options to purchase 0.9 million shares were exercisable with a weighted-average exercise price per share of $49.13.

Employee Stock Purchase Plan

The price at which common stock is purchased under the ESPP is equal to 85% of the fair market value of the common stock on the first day of the offering period or purchase date, whichever is lower. During the three months ended April 2, 2017, approximately 0.1 million shares were issued under the ESPP. As of April 2, 2017, there were approximately 14.1 million shares available for issuance under the ESPP.
 
Share Repurchases

On July 28, 2016, the Company’s Board of Directors authorized a share repurchase program, which supersedes all prior and available repurchase authorizations, to repurchase $250 million of outstanding common stock. During the three months ended April 2, 2017, the Company repurchased 0.6 million shares for $101 million, completing the share repurchase program. On May 4, 2017, the Company’s Board of Directors authorized an additional share repurchase program to repurchase $250 million of outstanding common stock. The repurchases may be completed under a 10b5-1 plan or at management’s discretion.
v3.7.0.1
Income Taxes
3 Months Ended
Apr. 02, 2017
Income Tax Disclosure [Abstract]  
Income Taxes
Income Taxes

The Company’s effective tax rate may vary from the U.S. federal statutory tax rate due to the change in the mix of earnings in tax jurisdictions with different statutory rates, benefits related to tax credits, and the tax impact of non-deductible expenses and other permanent differences between income before income taxes and taxable income. The effective tax rate for the three months ended April 2, 2017 was 30.8%. The variance from the U.S. federal statutory tax rate of 35% was primarily attributable to the offset by the mix of earnings in jurisdictions with lower statutory tax rates than the U.S. federal statutory tax rate, such as in Singapore and the United Kingdom, partially offset by the discrete tax impact of $150 million from the gain on the deconsolidation of GRAIL.
v3.7.0.1
Legal Proceedings
3 Months Ended
Apr. 02, 2017
Commitments and Contingencies Disclosure [Abstract]  
Legal Proceedings
Legal Proceedings

The Company is involved in various lawsuits and claims arising in the ordinary course of business, including actions with respect to intellectual property, employment, and contractual matters. In connection with these matters, the Company assesses, on a regular basis, the probability and range of possible loss based on the developments in these matters. A liability is recorded in the financial statements if it is believed to be probable that a loss has been incurred and the amount of the loss can be reasonably estimated. Because litigation is inherently unpredictable and unfavorable results could occur, assessing contingencies is highly subjective and requires judgments about future events. The Company regularly reviews outstanding legal matters to determine the adequacy of the liabilities accrued and related disclosures. The amount of ultimate loss may differ from these estimates. Each matter presents its own unique circumstances, and prior litigation does not necessarily provide a reliable basis on which to predict the outcome, or range of outcomes, in any individual proceeding. Because of the uncertainties related to the occurrence, amount, and range of loss on any pending litigation or claim, the Company is currently unable to predict their ultimate outcome, and, with respect to any pending litigation or claim where no liability has been accrued, to make a meaningful estimate of the reasonably possible loss or range of loss that could result from an unfavorable outcome. In the event that opposing litigants in outstanding litigations or claims ultimately succeed at trial and any subsequent appeals on their claims, any potential loss or charges in excess of any established accruals, individually or in the aggregate, could have a material adverse effect on the Company’s business, financial condition, results of operations, and/or cash flows in the period in which the unfavorable outcome occurs or becomes probable, and potentially in future periods.
v3.7.0.1
Segment Information (Notes)
3 Months Ended
Apr. 02, 2017
Segment Reporting [Abstract]  
Segment Reporting Disclosure [Text Block]
Segment Information

The Company has two reportable segments: Core Illumina and one segment related to the combined activities of the Company’s consolidated VIEs, GRAIL and Helix (Consolidated VIEs). Following the GRAIL deconsolidation on February 28, 2017, the Company’s Consolidated VIEs no longer include GRAIL. The Company reports segment information based on the management approach. This approach designates the internal reporting used by the Chief Operating Decision Maker (“CODM”) for making decisions and assessing performance as the source of the Company’s reportable segments. The CODM allocates resources and assesses the performance of each operating segment using information about its revenues and income (losses) from operations. Based on the information used by the CODM, the Company has determined its reportable segments as follows:

Core Illumina:

Core Illumina’s products and services serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. Core Illumina includes all operations of the Company, excluding the results of its consolidated VIEs.

Consolidated VIEs:

GRAIL: GRAIL was created to develop a blood test for early-stage cancer detection. GRAIL is currently in the early stages of developing this test and as such, has no revenues to date.

Helix: Helix was established to enable individuals to explore their genetic information by providing affordable sequencing and database services for consumers through third party partners, driving the creation of an ecosystem of consumer applications.

Management evaluates the performance of the Company’s operating segments based upon income (loss) from operations. The Company does not allocate expenses between segments. Core Illumina sells products and provides services to GRAIL and Helix in accordance with contractual agreements between the entities.

The following table presents the operating performance of each reportable segment (in millions):
 
Three Months Ended
 
April 2,
2017
 
April 3,
2016
Revenues:
 
 
 
Core Illumina
$
598

 
$
572

Consolidated VIEs
1

 

Elimination of intersegment revenues
(1
)
 

Consolidated revenues
$
598

 
$
572

 
 
 
 
Operating income (loss):
 
 
 
Core Illumina
$
84

 
$
130

Consolidated VIEs
(34
)
 
(9
)
Elimination of intersegment earnings
2

 

Consolidated operating income
$
52

 
$
121


The following table presents the total assets of each reportable segment (in millions):
 
April 2,
2017
 
January 1,
2017
Total assets:
 
 
 
Core Illumina
$
4,579

 
$
4,167

Consolidated VIEs
29

 
180

Elimination of intersegment assets
(10
)
 
(66
)
Consolidated total assets
$
4,598

 
$
4,281

v3.7.0.1
Basis of Presentation and Summary of Significant Accounting Policies (Policies)
3 Months Ended
Apr. 02, 2017
Accounting Policies [Abstract]  
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.
Consolidation
The unaudited condensed consolidated financial statements include the accounts of the Company, its wholly-owned subsidiaries, majority-owned or controlled companies, and variable interest entities (VIEs) for which the Company is the primary beneficiary. All intercompany transactions and balances have been eliminated in consolidation. Effective February 28, 2017, Illumina deconsolidated GRAIL, Inc.’s financial statements. In management’s opinion, the accompanying financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results for the interim periods presented.
Variable Interest Entities
The Company evaluates its ownership, contractual and other interests in entities that are not wholly-owned by the Company to determine if these entities are VIEs, and, if so, whether the Company is the primary beneficiary of the VIE. In determining whether the Company is the primary beneficiary of a VIE and is therefore required to consolidate the VIE, the Company applies a qualitative approach that determines whether it has both (1) the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and (2) the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE. The Company continuously assesses whether it is the primary beneficiary of a VIE as changes to existing relationships or future transactions may result in the consolidation or deconsolidation, as the case may be. The Company has not provided financial or other support during the periods presented to its VIEs that it was not previously contractually required to provide.
Equity Method Investments
The equity method is used to account for investments in which the Company has the ability to exercise significant influence, but not control, over the investee. Such investments are recorded within other assets, and the share of net income or losses of equity investments is recognized on a one quarter lag in other income, net.
Redeemable Noncontrolling Interests
Noncontrolling interests represent the portion of equity (net assets) in a consolidated entity that is not wholly-owned by the Company that is not attributable, directly or indirectly, to the Company. Noncontrolling interests with embedded contingent redemption features, such as put rights, that are not solely within the Company’s control are considered redeemable noncontrolling interests. Redeemable noncontrolling interests are presented outside of stockholders’ equity on the condensed consolidated balance sheets.
Segment Information
The Company is organized into three operating segments for purposes of evaluating its business operations and reviewing its financial results. One segment consists of Illumina’s core operations (Core Illumina). The other two segments relate to the activities of the Company’s consolidated variable interest entities (Consolidated VIEs), GRAIL and Helix, and are reported on an aggregate basis. Following the GRAIL deconsolidation on February 28, 2017, the Consolidated VIEs no longer include GRAIL. For further information on the Company’s segments, refer to note “9. Segment Information”
Fiscal Year
The Company’s fiscal year consists of 52 or 53 weeks ending the Sunday closest to December 31, with quarters of 13 or 14 weeks ending the Sunday closest to March 31, June 30, September 30, and December 31. The three months ended April 2, 2017 and April 3, 2016 were both 13 weeks.
Recently Adopted Accounting Pronouncements
In March 2016, the Financial Accounting Standards Board issued Accounting Standard Update (ASU) 2016-09, Compensation - Stock Compensation (Topic 718), which aims to simplify the accounting for share-based payment transactions, including accounting for income taxes, classification on the statement of cash flows, accounting for forfeitures, and classification of awards as either liabilities or equity. This ASU is effective for the Company beginning in the first quarter of 2017.

Under the ASU, excess tax benefits from share-based payment arrangements are classified as discrete items within the provision for income taxes, rather than recognizing excess tax benefits in additional paid-in capital. As of April 2, 2017, the Company recorded $45 million, net, to retained earnings primarily related to unrealized tax benefits associated with share-based compensation. During the three months ended April 2, 2017, excess tax benefits of $8 million were reflected as a component of the provision for income taxes.

In addition, under the ASU, excess income tax benefits from share-based compensation arrangements are classified as cash flow from operations, rather than cash flow from financing activities. The Company has elected to apply the cash flow classification guidance retrospectively and reclassified $59 million from financing activity to operating activity for the three months ended April 3, 2016.
Recent Issued Accounting Pronouncements
In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers (Topic 606). The new standard is based on the principle that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Since its initial release, the FASB has issued several amendments to the standard, which include clarification of accounting guidance related to identification of performance obligations, intellectual property licenses, and principal vs. agent considerations.

ASU 2014-09 and all subsequent amendments (collectively, the “new standards”) will be effective for the Company beginning in the first quarter of 2018 and may be applied using either the full retrospective method, in which case the standard would be applied to each prior reporting period presented, or the modified retrospective method, in which case the cumulative effect of applying the standard would be recognized at the date of initial application.

The Company formed an implementation team in 2016 to oversee adoption of the new standards. The implementation team has completed its initial assessment of the new standards, including a detailed review of the Company’s contract portfolio and revenue streams, particularly around product revenues, to identify potential differences in accounting as a result of the new standards. It performed an analysis of those differences and formed preliminary conclusions on the expected changes. While the team’s analysis to date suggests the impact of adoption will not have a material impact on the Company’s existing revenue accounting policies or financial statements, there are a number of steps in the team’s project plan that remain to be completed including: finalizing contract reviews, evaluating the impact on the Company’s services and other revenue streams, and working through anticipated changes to systems, business processes and controls to support the adoption of the new standards. Assuming the impact is not material, the Company expects to adopt the new standards using the modified retrospective method with an adjustment to beginning retained earnings for the cumulative effect of the change.

In January 2016, the Financial Accounting Standards Board issued ASU 2016-01, Financial Instruments - Overall (Subtopic 825-10), which requires equity investments (other than those accounted for under the equity method or those that result in consolidation) to be measured at fair value, with changes in fair value recognized in net income. ASU 2016-01 will be effective for the Company beginning in the first quarter of 2018. The Company anticipates that the adoption of ASU 2016-01 may increase the volatility of other income and expense, net, as a result of the remeasurement of the Company’s cost-method investments.

In February 2016, the Financial Accounting Standards Board issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. ASU 2016-02 will be effective for the Company beginning in the first quarter of 2019. ASU 2016-02 will be adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company is currently evaluating the impact of ASU 2016-02 on its consolidated financial statements.

In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available for sale debt securities. The ASU is effective for the Company beginning in the first quarter of 2020, with early adoption permitted.  The Company is currently evaluating the impact of ASU 2016-13 on its consolidated financial statements.

Earnings per Share
Basic earnings per share attributable to Illumina stockholders is computed based on the weighted average number of common shares outstanding during the period. Diluted earnings per share attributable to Illumina stockholders is computed based on the sum of the weighted average number of common shares and potentially dilutive common shares outstanding during the period. Per-share earnings of our VIEs are included in the Company’s consolidated basic and diluted earnings per share computations based on the Company’s share of the VIEs’ securities.

Potentially dilutive common shares consist of shares issuable under convertible senior notes, equity awards, and warrants. Convertible senior notes have a dilutive impact when the average market price of the Company’s common stock exceeds the applicable conversion price of the respective notes. Potentially dilutive common shares from equity awards and warrants are determined using the average share price for each period under the treasury stock method. In addition, proceeds from exercise of equity awards and warrants, and the average amount of unrecognized compensation expense for equity awards are assumed to be used to repurchase shares. In loss periods, basic net loss per share and diluted net loss per share are identical because the otherwise dilutive potential common shares become anti-dilutive and are therefore excluded.
Derivatives

The Company is exposed to foreign exchange rate risks in the normal course of business. The Company enters into foreign exchange contracts to manage foreign currency risks related to monetary assets and liabilities that are denominated in currencies other than the U.S. dollar. These foreign exchange contracts are carried at fair value in other assets or other liabilities and are not designated as hedging instruments. Changes in the value of the derivative are recognized in other income, net, along with the remeasurement gain or loss on the foreign currency denominated assets or liabilities.

Warranties

The Company generally provides a one-year warranty on instruments. Additionally, the Company provides a warranty on consumables through the expiration date, which generally ranges from six to twelve months after the manufacture date. At the time revenue is recognized, the Company establishes an accrual for estimated warranty expenses based on historical experience as well as anticipated product performance. The Company periodically reviews its warranty reserve for adequacy and adjusts the warranty accrual, if necessary, based on actual experience and estimated costs to be incurred. Warranty expense is recorded as a component of cost of product revenue.

v3.7.0.1
Basis of Presentation and Summary of Significant Accounting Policies (Tables)
3 Months Ended
Apr. 02, 2017
Accounting Policies [Abstract]  
Summary of Calculation of Weighted Average Shares used to Calculate Basic and Diluted Earnings Per Share, Earnings Per Share

The following table presents the calculation of weighted average shares used to calculate basic and diluted earnings per share (in millions):
 
Three Months Ended
 
April 2,
2017
 
April 3,
2016
Weighted average shares outstanding
146

 
147

Effect of potentially dilutive common shares from:
 
 
 
Equity awards
1

 
1

Weighted average shares used in calculating diluted earnings per share
147

 
148

Potentially dilutive shares excluded from calculation due to anti-dilutive effect
1

 
1



Summary of Calculation of Weighted Average Shares used to Calculate Basic and Diluted Earnings Per Share, Antidilutive Securities

The following table presents the calculation of weighted average shares used to calculate basic and diluted earnings per share (in millions):
 
Three Months Ended
 
April 2,
2017
 
April 3,
2016
Weighted average shares outstanding
146

 
147

Effect of potentially dilutive common shares from:
 
 
 
Equity awards
1

 
1

Weighted average shares used in calculating diluted earnings per share
147

 
148

Potentially dilutive shares excluded from calculation due to anti-dilutive effect
1

 
1

v3.7.0.1
Balance Sheet Account Details (Tables)
3 Months Ended
Apr. 02, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Summary of Short-term Investments
The following is a summary of short-term investments (in millions):
 
April 2, 2017
 
January 1, 2017
 
Amortized
Cost
 
Gross
Unrealized
Losses
 
Estimated
Fair Value
 
Amortized
Cost
 
Gross
Unrealized
Losses
 
Estimated
Fair Value
Available-for-sale securities:
 
 
 
 
 
 
 
 
 
 
 
Debt securities in government sponsored entities
$
31

 
$

 
$
31

 
$
34

 
$

 
$
34

Corporate debt securities
464

 
(1
)
 
463

 
478

 
(2
)
 
476

U.S. Treasury securities
304

 
(1
)
 
303

 
316

 
(2
)
 
314

Total available-for-sale securities
$
799

 
$
(2
)
 
$
797

 
$
828

 
$
(4
)
 
$
824

Summary of Contractual Maturities of Available-for-sale Debt Securities
Contractual maturities of available-for-sale debt securities as of April 2, 2017 were as follows (in millions):
 
Estimated
Fair Value
Due within one year
$
383

After one but within five years
414

Total
$
797


Summary of Inventory
Inventory consists of the following (in millions):
 
April 2,
2017
 
January 1,
2017
Raw materials
$
101

 
$
102

Work in process
162

 
161

Finished goods
36

 
37

Total inventory
$
299

 
$
300

Summary of Property and Equipment
Property and equipment, net consists of the following (in millions):
 
April 2,
2017
 
January 1,
2017
Leasehold improvements
$
273

 
$
270

Machinery and equipment
278

 
274

Computer hardware and software
168

 
156

Furniture and fixtures
26

 
24

Building
9

 
9

Construction in progress
326

 
307

Total property and equipment, gross
1,080

 
1,040

Accumulated depreciation
(346
)
 
(327
)
Total property and equipment, net
$
734

 
$
713


Summary of Changes in Goodwill

Changes to the Company’s goodwill balance during the three months ended April 2, 2017 are as follows (in millions):
 
Goodwill
Balance as of January 1, 2017
$
776

GRAIL deconsolidation
(5
)
Balance as of April 2, 2017
$
771


Summary of Accrued Liabilities

Accrued liabilities consist of the following (in millions):
 
April 2,
2017
 
January 1,
2017
Deferred revenue, current portion
$
122

 
$
121

Accrued compensation expenses
99

 
112

Accrued taxes payable
77

 
32

Customer deposits
31

 
20

Other
57

 
58

Total accrued liabilities
$
386

 
$
343


Summary of Changes in Reserve for Product Warranties
Changes in the Company’s reserve for product warranties during the three months ended April 2, 2017 and April 3, 2016 are as follows (in millions):
 
Three Months Ended
 
April 2,
2017
 
April 3,
2016
Balance at beginning of period
$
13

 
$
17

Additions charged to cost of product revenue
4

 
7

Repairs and replacements
(5
)
 
(8
)
Balance at end of period
$
12

 
$
16


Summary of Changes in Facility Exit Obligation Related to the Former Headquarters Lease

Changes in the Company’s facility exit obligation related to its former headquarters lease during the three months ended April 2, 2017 and April 3, 2016 are as follows (in millions):
 
Three Months Ended
 
April 2,
2017
 
April 3,
2016
Balance at beginning of period
$
19

 
$
22

Cash payments
(1
)
 
(1
)
Balance at end of period
$
18

 
$
21

Summary of Activity of Redeemable Noncontrolling Interests

The activity of the redeemable noncontrolling interests during the three months ended April 2, 2017 is as follows (in millions):
 
Redeemable Noncontrolling Interests
Balance as of January 1, 2017
$
44

Amount released from escrow
16

Vesting of redeemable equity awards
10

Net loss attributable to noncontrolling interests
(12
)
Adjustment up to the redemption value
12

Deconsolidation of GRAIL
(11
)
Balance as of April 2, 2017
$
59

v3.7.0.1
Fair Value Measurements (Tables)
3 Months Ended
Apr. 02, 2017
Fair Value Disclosures [Abstract]  
Summary of Hierarchy for Assets and Liabilities Measured at Fair Value on a Recurring Basis
The following table presents the Company’s hierarchy for assets and liabilities measured at fair value on a recurring basis as of April 2, 2017 and January 1, 2017 (in millions):
 
April 2, 2017
 
January 1, 2017
 
Level 1
 
Level 2
 
Level 3
 
Total
 
Level 1
 
Level 2
 
Level 3
 
Total
Assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Money market funds (cash equivalents)
$
689

 
$

 
$

 
$
689

 
$
386

 
$

 
$

 
$
386

Debt securities in government-sponsored entities

 
31

 

 
31

 

 
34

 

 
34

Corporate debt securities

 
463

 

 
463

 

 
476

 

 
476

U.S. Treasury securities
303

 

 

 
303

 
314

 

 

 
314

Deferred compensation plan assets

 
32

 

 
32

 

 
31

 

 
31

Total assets measured at fair value
$
992

 
$
526

 
$

 
$
1,518

 
$
700

 
$
541

 
$

 
$
1,241

Liabilities:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acquisition related contingent consideration liabilities
$

 
$

 
$
3

 
$
3

 
$

 
$

 
$
4

 
$
4

Deferred compensation liability

 
30

 

 
30

 

 
29

 

 
29

Total liabilities measured at fair value
$

 
$
30

 
$
3

 
$
33

 
$

 
$
29

 
$
4

 
$
33

v3.7.0.1
Debt (Tables)
3 Months Ended
Apr. 02, 2017
Debt Disclosure [Abstract]  
Summary of Information about Equity and Liability Components of Convertible Senior Notes Outstanding
The following table summarizes information about the equity and liability components of all convertible senior notes outstanding as of the period reported (dollars in millions). The fair values of the respective notes outstanding were measured based on quoted market prices, and is a Level 2 measurement.
 
April 2,
2017
 
January 1,
2017
Principal amount of convertible notes outstanding
$
1,150

 
$
1,150

Unamortized discount of liability component
(98
)
 
(105
)
Net carrying amount of liability component in long-term debt
$
1,052

 
$
1,045

Carrying value of equity component, net of debt issuance cost
$
161

 
$
161

Fair value of outstanding notes
$
1,178

 
$
1,108

Weighted-average remaining amortization period of discount on the liability component
3.4 years

 
3.6 years

v3.7.0.1
Share-based Compensation Expense (Tables)
3 Months Ended
Apr. 02, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Summary of Share-based Compensation Expense for all Stock Awards
Share-based compensation expense for all stock awards consists of the following (in millions):
 
Three Months Ended
 
April 2,
2017
 
April 3,
2016
Cost of product revenue
$
3

 
$
2

Research and development
14

 
11

Selling, general and administrative
33

 
22

Share-based compensation expense before taxes
50

 
35

Related income tax benefits
(11
)
 
(8
)
Share-based compensation expense, net of taxes
$
39

 
$
27

Summary of Assumptions used to Estimate the Weighted-Average Fair Value Per Share for Stock Purchase under the Employee Stock Purchase Plan
The assumptions used for the specified reporting periods and the resulting estimates of weighted-average fair value per share for stock purchased under the Employee Stock Purchase Plan (ESPP) during the three months ended April 2, 2017 are as follows:
 
Employee Stock Purchase Rights
Risk-free interest rate
0.65% - 0.83%

Expected volatility
44
%
Expected term
0.5 - 1.0 year

Expected dividends
0
%
Weighted-average fair value per share
$
46.67

v3.7.0.1
Stockholders' Equity (Tables)
3 Months Ended
Apr. 02, 2017
Equity [Abstract]  
Summary of Restricted Stock Activity and Related Information, Restricted Stock
The Company’s restricted stock activity and related information for the three months ended April 2, 2017 is as follows (units in thousands):
 
Restricted
Stock Awards
(RSA)
 
Restricted
Stock Units
(RSU)
 
Performance
Stock Units
(PSU)(1)
 
Weighted-Average
Grant-Date Fair Value per Share
 
 
 
 
RSA
 
RSU
 
PSU
Outstanding at January 1, 2017
32

 
2,293

 
460

 
$
136.30

 
$
141.80

 
$
158.66

Awarded

 
45

 
23

 
$

 
$
153.64

 
$
139.83

Vested

 
(127
)
 

 
$

 
$
95.06

 
$

Cancelled

 
(66
)
 
(33
)
 
$

 
$
146.83

 
$
185.43

Outstanding at April 2, 2017
32

 
2,145

 
450

 
$
136.30

 
$
144.69

 
$
155.72


______________________________________
(1)
The number of units reflect the estimated number of shares to be issued at the end of the performance period.

Summary of Restricted Stock Activity and Related Information, Performance Units
The Company’s restricted stock activity and related information for the three months ended April 2, 2017 is as follows (units in thousands):
 
Restricted
Stock Awards
(RSA)
 
Restricted
Stock Units
(RSU)
 
Performance
Stock Units
(PSU)(1)
 
Weighted-Average
Grant-Date Fair Value per Share
 
 
 
 
RSA
 
RSU
 
PSU
Outstanding at January 1, 2017
32

 
2,293

 
460

 
$
136.30

 
$
141.80

 
$
158.66

Awarded

 
45

 
23

 
$

 
$
153.64

 
$
139.83

Vested

 
(127
)
 

 
$

 
$
95.06

 
$

Cancelled

 
(66
)
 
(33
)
 
$

 
$
146.83

 
$
185.43

Outstanding at April 2, 2017
32

 
2,145

 
450

 
$
136.30

 
$
144.69

 
$
155.72


______________________________________
(1)
The number of units reflect the estimated number of shares to be issued at the end of the performance period.
Summary of Stock Option Activity Under all Stock Option Plans
The Company’s stock option activity under all stock option plans during the three months ended April 2, 2017 is as follows:
 
Options
(in thousands)
 
Weighted-Average
Exercise Price
Outstanding at January 1, 2017
1,045

 
$
48.56

Exercised
(107
)
 
$
43.65

Outstanding at April 2, 2017
938

 
$
49.13

v3.7.0.1
Segment Information (Tables)
3 Months Ended
Apr. 02, 2017
Segment Reporting [Abstract]  
Summary of Operating Performance and Assets by Segment
The following table presents the operating performance of each reportable segment (in millions):
 
Three Months Ended
 
April 2,
2017
 
April 3,
2016
Revenues:
 
 
 
Core Illumina
$
598

 
$
572

Consolidated VIEs
1

 

Elimination of intersegment revenues
(1
)
 

Consolidated revenues
$
598

 
$
572

 
 
 
 
Operating income (loss):
 
 
 
Core Illumina
$
84

 
$
130

Consolidated VIEs
(34
)
 
(9
)
Elimination of intersegment earnings
2

 

Consolidated operating income
$
52

 
$
121


The following table presents the total assets of each reportable segment (in millions):
 
April 2,
2017
 
January 1,
2017
Total assets:
 
 
 
Core Illumina
$
4,579

 
$
4,167

Consolidated VIEs
29

 
180

Elimination of intersegment assets
(10
)
 
(66
)
Consolidated total assets
$
4,598

 
$
4,281

v3.7.0.1
Basis of Presentation and Summary of Significant Accounting Policies - Narrative - Recently Adopted Accounting Principles (Details)
$ in Millions
3 Months Ended
Apr. 02, 2017
USD ($)
Accounting Policies [Abstract]  
Excess tax benefits from share-based compensation not yet recognized recorded in retained earnings $ 45
Excess tax benefits from share-based compensation recorded in provision for income taxes 8
Excess tax benefits from share-based compensation recorded in operating activities $ 59
v3.7.0.1
Basis of Presentation and Summary of Significant Accounting Policies - Summary of Calculation of Weighted Average Shares used to Calculate Basic and Diluted Earnings Per Share (Details) - shares
shares in Millions
3 Months Ended
Apr. 02, 2017
Apr. 03, 2016
Weighted average shares used to calculate basic and diluted earnings per share    
Weighted average shares outstanding 146 147
Effect of potentially dilutive common shares from:    
Equity awards 1 1
Weighted average shares used in calculating diluted earnings per share 147 148
Potentially dilutive shares excluded from calculation due to anti-dilutive effect 1 1
v3.7.0.1
Balance Sheet Account Details - Summary of Short-term Investments (Details) - USD ($)
$ in Millions
Apr. 02, 2017
Jan. 01, 2017
Available-for-sale securities:    
Amortized Cost $ 799 $ 828
Gross Unrealized Losses (2) (4)
Estimated Fair Value 797 824
Debt securities in government sponsored entities [Member]    
Available-for-sale securities:    
Amortized Cost 31 34
Estimated Fair Value 31 34
Corporate debt securities [Member]    
Available-for-sale securities:    
Amortized Cost 464 478
Gross Unrealized Losses (1) (2)
Estimated Fair Value 463 476
U.S. Treasury securities [Member]    
Available-for-sale securities:    
Amortized Cost 304 316
Gross Unrealized Losses (1) (2)
Estimated Fair Value $ 303 $ 314
v3.7.0.1
Balance Sheet Account Details - Summary of Contractual Maturities of Available-for-sale Debt Securities (Details)
$ in Millions
Apr. 02, 2017
USD ($)
Available-for-sale Securities, Debt Maturities, Fair Value, Fiscal Year Maturity [Abstract]  
Due within one year $ 383
After one but within five years 414
Total $ 797
v3.7.0.1
Balance Sheet Account Details - Narrative - Strategic Investments (Details) - USD ($)
$ in Millions
3 Months Ended
Apr. 02, 2017
Apr. 03, 2016
Jan. 01, 2017
Schedule of Investments [Line Items]      
Commitment in new venture capital investment fund $ 100    
Callable period 10 years    
Equity method investments $ 11   $ 10
Cost-Method Investee [Member]      
Schedule of Investments [Line Items]      
Revenue from transactions with Company's cost-method investments in non-publicly traded companies 23 $ 13  
Other Assets [Member]      
Schedule of Investments [Line Items]      
Company's cost-method investments in non-publicly traded companies $ 235   $ 57
v3.7.0.1
Balance Sheet Account Details - Summary of Inventory (Details) - USD ($)
$ in Millions
Apr. 02, 2017
Jan. 01, 2017
Inventory [Abstract]    
Raw materials $ 101 $ 102
Work in process 162 161
Finished goods 36 37
Total inventory $ 299 $ 300
v3.7.0.1
Balance Sheet Account Details - Summary of Property and Equipment (Details) - USD ($)
$ in Millions
Apr. 02, 2017
Jan. 01, 2017
Property, Plant and Equipment [Line Items]    
Total property and equipment, gross $ 1,080 $ 1,040
Accumulated depreciation (346) (327)
Total property and equipment, net 734 713
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Total property and equipment, gross 273 270
Machinery and equipment    
Property, Plant and Equipment [Line Items]    
Total property and equipment, gross 278 274
Computer hardware and software    
Property, Plant and Equipment [Line Items]    
Total property and equipment, gross 168 156
Furniture and fixtures    
Property, Plant and Equipment [Line Items]    
Total property and equipment, gross 26 24
Building    
Property, Plant and Equipment [Line Items]    
Total property and equipment, gross 9 9
Construction in progress    
Property, Plant and Equipment [Line Items]    
Total property and equipment, gross $ 326 $ 307
v3.7.0.1
Balance Sheet Account Details - Narrative - Property and Equipment (Details) - USD ($)
$ in Millions
3 Months Ended
Apr. 02, 2017
Apr. 03, 2016
Property, Plant and Equipment [Line Items]    
Accrued expenditures included in capital expenditures $ 60 $ 26
Construction in progress    
Property, Plant and Equipment [Line Items]    
Accrued expenditures included in capital expenditures $ 27 $ 10
v3.7.0.1
Balance Sheet Account Details - Summary of Changes in Goodwill (Details)
$ in Millions
3 Months Ended
Apr. 02, 2017
USD ($)
Goodwill [Roll Forward]  
Beginning balance $ 776
GRAIL deconsolidation (5)
Ending balance $ 771
v3.7.0.1
Balance Sheet Account Details - Narrative - Intangible Assets and Goodwill (Details)
$ in Millions
3 Months Ended
Apr. 02, 2017
USD ($)
Finite-Lived Intangible Assets [Line Items]  
Impairment of in-process research and development $ 5
Cost of Sales [Member]  
Finite-Lived Intangible Assets [Line Items]  
Impairment of finite-lived intangible assets $ 18
v3.7.0.1
Balance Sheet Account Details - Narrative - Derivatives (Details) - USD ($)
$ in Millions
Apr. 02, 2017
Jan. 01, 2017
Not Designated as Hedging Instrument [Member] | Foreign Exchange Forward [Member]    
Derivative [Line Items]    
Derivative, notional amount $ 92 $ 69
v3.7.0.1
Balance Sheet Account Details - Summary of Accrued Liabilities (Details) - USD ($)
$ in Millions
Apr. 02, 2017
Jan. 01, 2017
Accrued Liabilities, Current [Abstract]    
Deferred revenue, current portion $ 122 $ 121
Accrued compensation expenses 99 112
Accrued taxes payable 77 32
Customer deposits 31 20
Other 57 58
Total accrued liabilities $ 386 $ 343
v3.7.0.1
Balance Sheet Account Details - Narrative - Warranties (Details)
3 Months Ended
Apr. 02, 2017
Instruments [Member]  
Product Warranty Liability [Line Items]  
Warranty period 1 year
Consumables [Member] | Minimum [Member]  
Product Warranty Liability [Line Items]  
Warranty period 6 months
Consumables [Member] | Maximum [Member]  
Product Warranty Liability [Line Items]  
Warranty period 12 months
v3.7.0.1
Balance Sheet Account Details - Summary of Changes in Reserve for Product Warranties (Details) - USD ($)
$ in Millions
3 Months Ended
Apr. 02, 2017
Apr. 03, 2016
Reserve for product warranties [Roll Forward]    
Balance at beginning of period $ 13 $ 17
Additions charged to cost of product revenue 4 7
Repairs and replacements (5) (8)
Balance at end of period $ 12 $ 16
v3.7.0.1
Balance Sheet Account Details - Summary of Changes in Facility Exit Obligation Related to the Former Headquarters Lease (Details) - Facility Exit Obligation [Member] - USD ($)
$ in Millions
3 Months Ended
Apr. 02, 2017
Apr. 03, 2016
Headquarter Facility Exit Obligation [Roll Forward]    
Balance at beginning of period $ 19 $ 22
Cash payments (1) (1)
Balance at end of period $ 18 $ 21
v3.7.0.1
Balance Sheet Account Details - Narrative - Leases (Details)
$ in Millions
Feb. 22, 2017
USD ($)
Apr. 02, 2017
USD ($)
Leases
Jan. 01, 2017
USD ($)
Capital Leased Assets [Line Items]      
Number of projects accounted for under build-to-suit lease accounting | Leases   3  
Build-to-suit lease liability   $ 192 $ 223
Build-to-suit lease asset under construction   192 $ 223
February 2017 Lease Agreements      
Capital Leased Assets [Line Items]      
Capital lease term 15 years    
Future minimum payment due for lease addition in period $ 46    
GRAIL, Inc. [Member]      
Capital Leased Assets [Line Items]      
Build-to-suit lease liability   58  
Build-to-suit lease asset under construction   $ 58  
v3.7.0.1
Balance Sheet Account Details - Narrative - Investment in Consolidated Variable Interest Entities (Details) - USD ($)
shares in Millions, $ in Millions
1 Months Ended 3 Months Ended
Feb. 28, 2017
Jul. 03, 2016
Jan. 31, 2016
Apr. 02, 2017
Apr. 03, 2016
Feb. 27, 2017
Jan. 01, 2017
Jan. 03, 2016
Jul. 31, 2015
Variable Interest Entity [Line Items]                  
Contributions from noncontrolling interest owners       $ 16 $ 80        
Noncontrolling shareholders interest percentage       50.00%          
Cash and cash equivalents attributable to variable interest entities       $ 981 $ 755   $ 735 $ 769  
Variable Interest Entity, Primary Beneficiary [Member]                  
Variable Interest Entity [Line Items]                  
Cash and cash equivalents attributable to variable interest entities       $ 5          
GRAIL, Inc. [Member]                  
Variable Interest Entity [Line Items]                  
Deemed dividend   $ 10              
Deemed dividend, tax effect   $ 10              
GRAIL, Inc. [Member] | Variable Interest Entity, Primary Beneficiary [Member]                  
Variable Interest Entity [Line Items]                  
Equity ownership interest percentage           52.00%      
Series A financing     $ 120            
Amount contributed     40            
Contributions from noncontrolling interest owners     $ 80            
Helix Holdings I, LLC [Member] | Variable Interest Entity, Primary Beneficiary [Member]                  
Variable Interest Entity [Line Items]                  
Equity ownership interest percentage       50.00%         50.00%
GRAIL Class B [Member] | GRAIL, Inc. [Member] | Variable Interest Entity, Primary Beneficiary [Member]                  
Variable Interest Entity [Line Items]                  
Series A financing $ 900                
Stock exchanged (in shares)     113            
GRAIL Class A-1 Convertible [Member] | GRAIL, Inc. [Member] | Variable Interest Entity, Primary Beneficiary [Member]                  
Variable Interest Entity [Line Items]                  
Shares authorized by GRAIL issued to Illumina   98              
Illumina Class B [Member] | GRAIL, Inc. [Member] | Variable Interest Entity, Primary Beneficiary [Member]                  
Variable Interest Entity [Line Items]                  
Shares authorized by Illumina issued to GRAIL   98              
v3.7.0.1
Balance Sheet Account Details - Narrative - Deconsolidation of GRAIL, Inc. (Details) - USD ($)
shares in Millions, $ in Millions
1 Months Ended 2 Months Ended 3 Months Ended
Feb. 28, 2017
Jan. 31, 2016
Feb. 28, 2017
Apr. 02, 2017
Apr. 30, 2017
Feb. 27, 2017
Jan. 01, 2017
Variable Interest Entity [Line Items]              
Proceeds from sale of GRAIL preferred stock       $ 278      
Gain on deconsolidation of GRAIL       453      
Portion of gain on deconsolidation related to remeasurement of Company's retained equity interest       159      
Other Assets [Member]              
Variable Interest Entity [Line Items]              
Cost-method investments       235     $ 57
GRAIL, Inc. [Member] | Other Assets [Member]              
Variable Interest Entity [Line Items]              
Cost-method investments       171      
Variable Interest Entity, Primary Beneficiary [Member] | GRAIL, Inc. [Member]              
Variable Interest Entity [Line Items]              
GRAIL Series B preferred financing   $ 120          
Proceeds from sale of GRAIL preferred stock       $ 278      
Equity ownership interest percentage           52.00%  
Cost-method investment ownership percentage       19.00%      
Cost-method investment voting interest percentage       13.00%      
Percentage of entity's losses absorbed     50.00%        
Variable Interest Entity, Primary Beneficiary [Member] | GRAIL, Inc. [Member] | GRAIL Class B [Member]              
Variable Interest Entity [Line Items]              
GRAIL Series B preferred financing $ 900            
Variable Interest Entity, Primary Beneficiary [Member] | GRAIL, Inc. [Member] | GRAIL Class A Preferred [Member]              
Variable Interest Entity [Line Items]              
Shares repurchased by GRAIL from Illumina 35            
Remaining shares of GRAIL owned by Illumina       5      
Variable Interest Entity, Primary Beneficiary [Member] | GRAIL, Inc. [Member] | GRAIL Class A-1 Convertible [Member]              
Variable Interest Entity [Line Items]              
Shares repurchased by GRAIL from Illumina 34            
Variable Interest Entity, Primary Beneficiary [Member] | GRAIL, Inc. [Member] | GRAIL Class A Common [Member]              
Variable Interest Entity [Line Items]              
Remaining shares of GRAIL owned by Illumina       78      
Subsequent Event [Member] | Variable Interest Entity, Primary Beneficiary [Member] | GRAIL, Inc. [Member] | GRAIL Class B [Member]              
Variable Interest Entity [Line Items]              
Purchase obligation of noncontrolling interest shares         $ 14    
v3.7.0.1
Balance Sheet Account Details - Summary of Activity of Redeemable Noncontrolling Interests (Details)
$ in Millions
3 Months Ended
Apr. 02, 2017
USD ($)
Increase (Decrease) in Redeemable Noncontrolling Interests [Roll Forward]  
Balance as of January 1, 2017 $ 44
Amount released from escrow 16
Vesting of redeemable equity awards 10
Net loss attributable to noncontrolling interests (12)
Adjustment up to the redemption value 12
Deconsolidation of GRAIL (11)
Balance as of April 2, 2017 $ 59
v3.7.0.1
Fair Value Measurements - Summary of Hierarchy for Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)
$ in Millions
Apr. 02, 2017
Jan. 01, 2017
Assets:    
Available-for-sale securities $ 797 $ 824
Debt securities in government sponsored entities [Member]    
Assets:    
Available-for-sale securities 31 34
Corporate debt securities [Member]    
Assets:    
Available-for-sale securities 463 476
U.S. Treasury securities [Member]    
Assets:    
Available-for-sale securities 303 314
Fair Value, Measurements, Recurring [Member]    
Assets:    
Deferred compensation plan assets 32 31
Total assets measured at fair value 1,518 1,241
Liabilities:    
Acquisition related contingent consideration liabilities 3 4
Deferred compensation liability 30 29
Total liabilities measured at fair value 33 33
Fair Value, Measurements, Recurring [Member] | Debt securities in government sponsored entities [Member]    
Assets:    
Available-for-sale securities 31 34
Fair Value, Measurements, Recurring [Member] | Corporate debt securities [Member]    
Assets:    
Available-for-sale securities 463 476
Fair Value, Measurements, Recurring [Member] | U.S. Treasury securities [Member]    
Assets:    
Available-for-sale securities 303 314
Fair Value, Measurements, Recurring [Member] | Money market funds (cash equivalents) [Member]    
Assets:    
Money market funds (cash equivalents) 689 386
Fair Value, Measurements, Recurring [Member] | Level 1 [Member]    
Assets:    
Total assets measured at fair value 992 700
Fair Value, Measurements, Recurring [Member] | Level 1 [Member] | U.S. Treasury securities [Member]    
Assets:    
Available-for-sale securities 303 314
Fair Value, Measurements, Recurring [Member] | Level 1 [Member] | Money market funds (cash equivalents) [Member]    
Assets:    
Money market funds (cash equivalents) 689 386
Fair Value, Measurements, Recurring [Member] | Level 2 [Member]    
Assets:    
Deferred compensation plan assets 32 31
Total assets measured at fair value 526 541
Liabilities:    
Deferred compensation liability 30 29
Total liabilities measured at fair value 30 29
Fair Value, Measurements, Recurring [Member] | Level 2 [Member] | Debt securities in government sponsored entities [Member]    
Assets:    
Available-for-sale securities 31 34
Fair Value, Measurements, Recurring [Member] | Level 2 [Member] | Corporate debt securities [Member]    
Assets:    
Available-for-sale securities 463 476
Fair Value, Measurements, Recurring [Member] | Level 3 [Member]    
Liabilities:    
Acquisition related contingent consideration liabilities 3 4
Total liabilities measured at fair value $ 3 $ 4
v3.7.0.1
Debt - Narrative (Details) - Convertible Senior Notes [Member]
$ / shares in Units, $ in Millions
1 Months Ended 3 Months Ended
Jun. 29, 2014
USD ($)
$ / shares
Apr. 02, 2017
USD ($)
day
Dec. 31, 2011
USD ($)
2019 Notes [Member]      
Debt Instrument [Line Items]      
Principal amount | $ $ 633 $ 633  
Interest rate on convertible senior notes   0.00%  
Effective interest rate used to measure fair value of converted notes upon conversion 2.90%    
Conversion rate 0.0039318    
Conversion price (in dollars per share) | $ / shares $ 254.34    
Threshold note trading days   5  
Threshold consecutive note trading days   10 days  
Threshold percentage of note price trigger   98.00%  
Threshold common stock trading days   20  
Threshold consecutive common stock trading days   30 days  
Threshold percentage of common stock price trigger   130.00%  
2021 Notes [Member]      
Debt Instrument [Line Items]      
Principal amount | $ $ 517 $ 517  
Interest rate on convertible senior notes   0.50%  
Effective interest rate used to measure fair value of converted notes upon conversion 3.50%    
Conversion rate 0.0039318    
Conversion price (in dollars per share) | $ / shares $ 254.34    
Threshold note trading days   5  
Threshold consecutive note trading days   10 days  
Threshold percentage of note price trigger   98.00%  
Threshold common stock trading days   20  
Threshold consecutive common stock trading days   30 days  
Threshold percentage of common stock price trigger   130.00%  
2016 Notes [Member]      
Debt Instrument [Line Items]      
Principal amount | $     $ 920
Interest rate on convertible senior notes     0.25%
Effective interest rate used to measure fair value of converted notes upon conversion     4.50%
v3.7.0.1
Debt - Summary of Information about Equity and Liability Components of Convertible Senior Notes Outstanding (Details) - Convertible Senior Notes [Member] - USD ($)
$ in Millions
3 Months Ended 12 Months Ended
Apr. 02, 2017
Jan. 01, 2017
Summarized information about equity and liability components of convertible senior notes    
Principal amount of convertible notes outstanding $ 1,150 $ 1,150
Unamortized discount of liability component (98) (105)
Net carrying amount of liability component in long-term debt 1,052 1,045
Carrying value of equity component, net of debt issuance cost $ 161 $ 161
Weighted-average remaining amortization period of discount on the liability component 3 years 5 months 3 years 7 months
Fair Value, Inputs, Level 2 [Member]    
Summarized information about equity and liability components of convertible senior notes    
Fair value of outstanding notes $ 1,178 $ 1,108
v3.7.0.1
Debt - Other Narrative (Details) - USD ($)
$ in Millions
Apr. 02, 2017
Jan. 01, 2017
Line of Credit Facility [Line Items]    
Long-term debt, current portion $ 1 $ 1
Long-term debt 1,055 1,048
Helix Holdings I, LLC [Member] | Line of Credit [Member]    
Line of Credit Facility [Line Items]    
Long-term debt, current portion 1 1
Long-term debt $ 3 $ 3
v3.7.0.1
Share-based Compensation Expense - Summary of Share-based Compensation Expense for all Stock Awards (Details) - USD ($)
$ in Millions
3 Months Ended
Apr. 02, 2017
Apr. 03, 2016
Share-based Compensation    
Share-based compensation expense before taxes $ 50 $ 35
Related income tax benefits (11) (8)
Share-based compensation expense, net of taxes 39 27
Cost of product revenue [Member]    
Share-based Compensation    
Share-based compensation expense before taxes 3 2
Research and development [Member]    
Share-based Compensation    
Share-based compensation expense before taxes 14 11
Selling, general and administrative [Member]    
Share-based Compensation    
Share-based compensation expense before taxes $ 33 $ 22
v3.7.0.1
Share-based Compensation Expense - Summary of Assumptions used to Estimate the Weighted-Average Fair Value Per Share for Stock Purchase under the Employee Stock Purchase Plan (Details) - Employee Stock [Member]
3 Months Ended
Apr. 02, 2017
$ / shares
Assumptions used to estimate the fair value per share of employee stock purchase rights granted  
Expected volatility, minimum 44.00%
Expected volatility, maximum 44.00%
Expected dividends 0.00%
Weighted-average fair value per share (in dollars per share) $ 46.67
Minimum [Member]  
Assumptions used to estimate the fair value per share of employee stock purchase rights granted  
Risk-free interest rate 0.65%
Expected term 6 months
Maximum [Member]  
Assumptions used to estimate the fair value per share of employee stock purchase rights granted  
Risk-free interest rate 0.83%
Expected term 1 year
v3.7.0.1
Share-based Compensation Expense - Narrative (Details)
$ in Millions
3 Months Ended
Apr. 02, 2017
USD ($)
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Unrecognized compensation cost related to stock options, restricted stock, and ESPP shares granted to date $ 316
Weighted-average period of unrecognized compensation cost related to stock options, restricted stock, and ESPP shares granted to date 2 years 7 months
v3.7.0.1
Stockholders' Equity - Narrative (Details)
shares in Millions
Apr. 02, 2017
shares
2015 Illumina and 2005 Solexa Plans [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Shares available for issuance (in shares) 6.2
v3.7.0.1
Stockholders' Equity - Summary of Restricted Stock Activity and Related Information (Details)
shares in Thousands
3 Months Ended
Apr. 02, 2017
$ / shares
shares
Restricted Stock Awards (RSA) [Member]  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]  
Outstanding at period start (in shares) | shares 32
Outstanding at period end (in shares) | shares 32
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]  
Weighted-Average Grant Date Fair Value per Share, Outstanding at period start (in dollars per share) | $ / shares $ 136.30
Weighted-Average Grant Date Fair Value per Share, Outstanding at period end (in dollars per share) | $ / shares $ 136.30
Restricted Stock Units (RSU) [Member]  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]  
Outstanding at period start (in shares) | shares 2,293
Awarded (in shares) | shares 45
Vested (in shares) | shares (127)
Cancelled (in shares) | shares (66)
Outstanding at period end (in shares) | shares 2,145
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]  
Weighted-Average Grant Date Fair Value per Share, Outstanding at period start (in dollars per share) | $ / shares $ 141.80
Weighted-Average Grant Date Fair Value per Share, Awarded (in dollars per share) | $ / shares 153.64
Weighted-Average Grant Date Fair Value per Share, Vested (in dollars per share) | $ / shares 95.06
Weighted-Average Grant Date Fair Value per Share, Cancelled (in dollars per share) | $ / shares 146.83
Weighted-Average Grant Date Fair Value per Share, Outstanding at period end (in dollars per share) | $ / shares $ 144.69
Performance Stock Units (PSU) [Member]  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]  
Outstanding at period start (in shares) | shares 460
Awarded (in shares) | shares 23
Cancelled (in shares) | shares (33)
Outstanding at period end (in shares) | shares 450
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]  
Weighted-Average Grant Date Fair Value per Share, Outstanding at period start (in dollars per share) | $ / shares $ 158.66
Weighted-Average Grant Date Fair Value per Share, Awarded (in dollars per share) | $ / shares 139.83
Weighted-Average Grant Date Fair Value per Share, Cancelled (in dollars per share) | $ / shares 185.43
Weighted-Average Grant Date Fair Value per Share, Outstanding at period end (in dollars per share) | $ / shares $ 155.72
v3.7.0.1
Stockholders' Equity - Summary of Stock Option Activity Under all Stock Option Plans (Details)
shares in Thousands
3 Months Ended
Apr. 02, 2017
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]  
Options, Outstanding at period start (in shares) | shares 1,045
Options, Exercised (in shares) | shares (107)
Options, Outstanding at period end (in shares) | shares 938
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]  
Weighted-Average Exercise Price, Options, Outstanding at period start (in dollars per share) | $ / shares $ 48.56
Weighted-Average Exercise Price, Options, Exercised (in dollars per share) | $ / shares 43.65
Weighted-Average Exercise Price, Options, Outstanding at period end (in dollars per share) | $ / shares $ 49.13
v3.7.0.1
Stockholders' Equity - Narrative - Stock Options (Details)
shares in Millions
Apr. 02, 2017
$ / shares
shares
Equity [Abstract]  
Stock options exercisable (in shares) | shares 0.9
Stock options exercisable outstanding weighted-average exercise price per share (in dollars per share) | $ / shares $ 49.13
v3.7.0.1
Stockholders' Equity - Narrative - Employee Stock Purchase Plan (Details) - ESPP [Member] - Employee Stock [Member]
shares in Millions
3 Months Ended
Apr. 02, 2017
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Specified percentage of the fair market value of the common stock on the first or last day of the offering period whichever is lower at which stock is purchased 85.00%
Total shares issued under the ESPP (in shares) 0.1
Shares available for issuance (in shares) 14.1
v3.7.0.1
Stockholders' Equity - Narrative - Share Repurchases (Details) - USD ($)
shares in Millions, $ in Millions
3 Months Ended
Apr. 02, 2017
May 04, 2017
Jul. 28, 2016
Class of Stock [Line Items]      
Common stock repurchases $ 101    
Common Stock [Member]      
Class of Stock [Line Items]      
Repurchase of common shares (in shares) 0.6    
Common stock repurchases $ 101    
Common Stock [Member] | July 2016 Share Repurchase Plan [Member]      
Class of Stock [Line Items]      
Stock repurchase program, authorized amount     $ 250
Subsequent Event [Member] | Common Stock [Member] | May 2017 Share Repurchase Plan [Member]      
Class of Stock [Line Items]      
Stock repurchase program, authorized amount   $ 250  
v3.7.0.1
Income Taxes - Narrative (Details)
$ in Millions
3 Months Ended
Apr. 02, 2017
USD ($)
Income Tax Disclosure [Abstract]  
Effective tax rate 30.80%
U.S. federal statutory tax rate 35.00%
Tax impact from the gain on the deconsolidation of GRAIL $ 150
v3.7.0.1
Segment Information (Details) - USD ($)
$ in Millions
3 Months Ended
Apr. 02, 2017
Apr. 03, 2016
Jan. 01, 2017
Segment Reporting Information [Line Items]      
Segment revenues $ 598 $ 572  
Segment operating income (loss) 52 121  
Segment assets 4,598   $ 4,281
Core Illumina      
Segment Reporting Information [Line Items]      
Segment revenues 598 572  
Segment operating income (loss) 84 130  
Segment assets 4,579   4,167
Consolidated VIEs      
Segment Reporting Information [Line Items]      
Segment revenues 1    
Segment operating income (loss) (34) $ (9)  
Segment assets 29   180
Intersegment Eliminations      
Segment Reporting Information [Line Items]      
Segment revenues (1)    
Segment operating income (loss) 2    
Segment assets $ (10)   $ (66)